ReviewHuman vaccines & immunotherapeutics2026
The promise of immunotherapy in the treatment of sarcoma: A state-of-the-art review of practice changing research and future directions.
Review in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Soft-tissue sarcoma (STS) poses unique challenges to treatment due to its rarity and heterogeneity. Comprised of multiple histologies which, among other characteristics, differ in their genetic makeup, tumor microenvironment, recurrence patterns and therefore response to treatment, STS is treated primarily with surgical resection, with systemic therapy used in high-risk or metastatic cases. In the era of immunotherapy, STS has been characterized as predominantly immune-cold with few histologies demonstrating consistent robust responses to checkpoint inhibition in the metastatic setting. Strategies to improve checkpoint inhibition responsiveness, such as combination therapies and treatment in the neoadjuvant setting, have shown promise in certain sarcoma subtypes. Other immunotherapeutic approaches, such as adoptive cellular therapies, as well as development of reliable biomarkers for response to immune checkpoint inhibitors, are the subject of ongoing research in this field.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.